<DOC>
	<DOCNO>NCT00002413</DOCNO>
	<brief_summary>The purpose study see safe effective give MKC-442 plus least two anti-HIV drug patient never treat nonnucleoside reverse transcriptase inhibitor treat nucleoside reverse transcriptase inhibitor protease inhibitor . This study also determine long drug combination include MKC-442 effective .</brief_summary>
	<brief_title>A Study MKC-442 HIV-Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Emivirine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Based medical history , medical condition , prior use antiretroviral drug , genotypic analysis predominant strain HIV1 isolate plasma , administration least 2 available antiviral agent prescription may give MKC422 . Patients must : HIV infection HIV1 RNA great equal 2,000 Roche Amplicor method , within 30 day entry . Prior Medication : Allowed : Prior nucleoside reverse transcriptase protease inhibitor . Cytotoxic chemotherapy 30 day prior entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malabsorption severe chronic diarrhea within 30 day prior entry , inability consume adequate oral intake chronic nausea , emesis , abdominal esophageal discomfort . Inadequately controlled seizure disorder . Acute clinically significant medical event within 30 day screen . Any clinical laboratory abnormality great Grade 3 toxicity , exception list laboratory value . Prior Medication : Excluded : Nonnucleoside reverse transcriptase inhibitor therapy . Any unapproved experimental antiretroviral therapy . Prior Treatment : Excluded : Radiation therapy within 30 day entry , except local lesion . Transfusion blood blood product within 21 day screen . Risk Behavior : Excluded : Active substance abuse may interfere compliance protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>MKC 442</keyword>
</DOC>